Aura Biosciences, Inc. (AURA): Total Assets
$169.43M
As of 2025-12-31
$348.13M
As of 2026-06-30
-8.9%
3-year compound annual growth
+50.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $169.43M | -7.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $182.50M | -28.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $255.07M | +13.9% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $223.94M | +39.9% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $160.03M | +624.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $22.10M | n/a | 2022-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $169.43M | -7.2% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $172.81M | +291.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $165.08M | -10.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $181.20M | +83.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
Compare AURA, SABS, STRO, CABA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗